Title: Longitudinal changes of white matter hyperintensities in sporadic small vessel disease: a systematic review and meta-analysis

Authors: Angela CC Jochems, MSc^a, Carmen Arteaga, MD^a, Francesca M Chappell, PhD^a, Tuula Ritakari, PhD^a, Monique Hooley, PhD^b, Fergus N Doubal, PhD^a, Susana Muñoz Maniega, PhD^a, Joanna M Wardlaw, MD^a

Affiliations: ^aCentre for Clinical Brain Sciences and UK Dementia Research Institute at the University of Edinburgh, Edinburgh, United Kingdom; ^bCentre for Discovery Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom

Corresponding author: Joanna M Wardlaw

Abstract

Background and objectives. White matter hyperintensities (WMH) are frequent imaging features of small vessel disease (SVD) and related to poor clinical outcomes. WMH progression over time is well described, but regression was also noted recently, although the frequency and associated factors are unknown. This systematic review and meta-analysis aims to assess longitudinal intra-individual WMH volume changes in sporadic SVD.

Methods. Following PRISMA guidelines we searched EMBASE and MEDLINE for papers up to 28 January 2022 on WMH volume changes using MRI on ≥2 time-points in adults with sporadic SVD. We classified populations (healthy/community-dwelling, stroke, cognitive, other vascular risk factors, depression) based on study characteristics. We performed random-effects meta-analyses with Knapp-Hartung adjustment to determine mean WMH volume change (change in mL, % of intracranial volume [%ICV], or mL/year), 95%CI and prediction intervals (PI, limits of increase and decrease) using unadjusted data. Risk of Bias Assessment tool for Non-randomised Studies (RoBANS) was used to assess risk of bias. **Results.** Forty papers, 10,932 participants, met the inclusion criteria. Mean WMH volume increased over time by: 1.74 mL (95% CI 1.23, 2.26; PI -1.24, 4.73 mL; 27 papers, N=7411, mean time interval 2.7 years, SD=1.65); 0.25%ICV (95% CI 0.14, 0.36; PI -0.06, 0.56; 6 papers, N=1071, mean time interval 3.5 years, SD =1.54); or 0.61 mL/year (95% CI 0.37, 0.85; PI -0.25, 1.46; 7 papers, N=2450). Additionally, 13 papers specifically mentioned and/or provided data on WMH regression, which occurred in asymptomatic, stroke, and cognitive presentations of SVD.

Discussion. Net mean WMH volume increases over time mask wide-ranging change (e.g. mean increase of 1³/₄mL ranging from 1¹/₄mL decrease to 4³/₄ml increase), with regression documented explicitly in up to 1/3 of participants. More knowledge on underlying mechanisms, associated factors and clinical correlates is needed, as WMH regression could be an important intervention target.

Introduction

White matter hyperintensities (WMH) of presumed vascular origin are the most common neuroimaging feature of small vessel disease (SVD), a disorder of the cerebral microvessels. WMH are visible on MRI as hyperintense lesions on T2-weighted and hypointense on T1-weighted sequences.¹

Around 11-15% of a general middle-aged population have one or more WMH, increasing to over 90% in people aged over 80. WMH are associated with risk factors including age, hypertension, smoking, and diabetes² and with symptoms such as apathy, fatigue, delirium, cognitive decline and increased risk of stroke and dementia.³

WMH are thought to indicate areas of permanent white matter damage due to demyelination and axon loss.³ In longitudinal studies, WMH progression over time is a common finding, while WMH regression has only been noted in a few recent studies,^{4, 5} but otherwise has been disregarded as measurement error or overlooked. If a genuine finding, then WMH regression might suggest that WMH do not only indicate permanently damaged brain tissue. A better understanding of the frequency and factors associated with WMH regression could help identify potential interventions to delay WMH progression and the devastating clinical consequences.

We performed this systematic review and meta-analysis to assess longitudinal intraindividual WMH volume changes in sporadic SVD over time using volumetric MRI measurements and progression rates.

Methods

Search strategy and selection criteria

We searched EMBASE and MEDLINE from January 1985, when MRI became more widely implemented in clinical practice, to January 28, 2022, for studies investigating longitudinal quantification of WMH volume on MRI on at least two different times points in adults over 18 years old (eAppendix 1: Search strategy). We designed the search strategy and complied with the Preferred Reporting in Systematic Review and Meta-Analysis (PRISMA) guidelines.

We supplemented this search with hand-searched articles from January 2012 to December 22, 2020, in Stroke, Journal of Cerebral Blood Flow and Metabolism, and Neurology. We registered the protocol on PROSPERO (CRD42018080548) on January 23, 2018. We included published full-text articles from peer-reviewed longitudinal studies that used MRI to quantify WMH volumes, defined according to STRIVE criteria¹, on at least two different time points and that provided numerical analysis of WMH volume change between the time points. Studies included randomised trials, non-randomised trials, cohort studies, and case-control studies. For data from a single cohort published more than once, we included the most relevant paper with the largest sample size and years of follow-up and most useable data to minimise duplication or overlapping samples. We excluded studies of SVD attributable to hereditary causes (e.g., CADASIL, CARASIL) or WMH attributable to other causes (e.g., multiple sclerosis, inflammatory disorders including primary angiitis, secondary vasculitis, post-infectious, and paraneoplastic syndromes).

Title and abstract screening and duplicate paper removal were done independently by one reviewer (CA, ACCJ, TR, MH). A second reviewer screened a random 10% sample of titles and abstracts. Full-text review was assessed independently by one reviewer, and a second reviewer screened a random 20% sample of the full texts (CA, ACCJ) using Covidence software (https://www.covidence.org/). Data extraction was performed by a single reviewer using a pre-specified data collection form (eTable 1), and a second reviewer double-extracted a random 20% sample. Two reviewers used RoBANS (risk of bias assessment tool for non-randomised studies)⁶ to assess all studies including randomised trials, for participant selection, adjustment for confounders, adequacy of WMH descriptors, blinding, incomplete outcome data, and selective outcome reporting (eTable 2). Any disagreements were resolved by discussion between reviewers (CA, ACCJ) with the help of a senior reviewer (JMW).

Data extraction

We extracted information on study design, demographic characteristics, vascular risk factors, study population (i.e. healthy and/or community-dwelling population (healthy/CD), patients with depression, patients with stroke, cognitive presentation or other vascular risk factors (VRF) presentations), and follow-up period.

We extracted data related to MRI assessment, including WMH volumes per time point and WMH change between those time points, adjustment of WMH measurements to e.g., intracranial volume, total brain volume; methods of WMH calculation and predictors of change. WMH volume data are often skewed and are log transformed to normalise the data before being used in analyses. We aimed to use unadjusted raw data where possible to reflect real intra-individual changes and include the whole range of least and most growth. We selected studies that provided unadjusted mean raw WMH volume change, e.g. mL, cm³ and cc, changes in volume expressed as a percentage of intracranial volume (%ICV), or an annual change rate (e.g. mL per year). We extracted the mean or median with corresponding SD, IQR, range, 95% CI, SEM, and if provided, the baseline WMH volumes. If studies did not provide mean and SD of WMH volume change, we calculated the mean and standard deviation from the sample size, median, range, IQR, SEM or 95% CI.⁷ We extracted data from studies that reported volumes per group and for the entire cohort; when the volume for the entire cohort was not available, data for the separate groups were included. For studies that did not report complete volumetric assessments, or where the data were not useable in the meta-analysis, we extracted relevant measures to perform a narrative summary of findings.

Statistical analysis

We used random-effects meta-analyses (because of expected between-study heterogeneity) to calculate mean WMH change, its confidence interval and prediction interval (PI) using untransformed raw means. More than two studies are needed to calculate a PI. The PI is an estimate of an interval, based on data that have already been observed and are included in

the meta-analysis, in which future observations will fall, with 95% confidence. In contrast to the CI, it indicates the range of least and most WMH volume change in a sample, while the CI indicates the range of mean change. We applied the Knapp-Hartung adjustment to control for uncertainty regarding between-study heterogeneity and calculate the confidence interval around the pooled mean.⁸ We planned additional explorative subgroup analyses by study population group (e.g. stroke), age strata, and time lapse between MRIs, when possible. Populations were assigned based on the study characteristics. When papers reported subgroups, e.g. cases, controls, or treatment groups, these were entered as separate groups and mentioned in the main meta-analyses unless data from the total group was used. However, there were insufficient data to assess trial interventions. We assessed heterogeneity by visual assessment of the forest plots and by calculating the l² and τ^2 statistics to estimate the between-study variance with a restricted maximum-likelihood estimator. We used R version 4.0.2 (https://www.R-project.org/) and the 'meta' package.⁹

Data availability

Data used in this study are available upon reasonable request from the corresponding author.

Results

Our search yielded 1206 publications and our manual search provided 197 further publications (Figure 1). After title and abstract screening, 248 full texts were assessed for eligibility. Most papers were excluded because they only reported WMH volumes at one time point, reported no WMH volumes at all, or were superceded by a publication from the same study reporting more complete relevant data. This left 64 papers that were relevant to the review question, but 24 papers did not provide raw/unadjusted WMH volumes and instead used log-transformed, estimated volumes, or percentages of change compared to baseline volumes. Therefore, 40 papers were included in meta-analysis, comprising 39 different studies and 10,932 participants (summarised in eTables 3-5), time between scans median

2.6 years (range 0.25 - 8.7 years). For 13/40 papers included in the meta-analysis we had to estimate the mean and SD. The 24 relevant papers that did not provide useable WMH change data are summarised in text, eResults 1-2 and eTable 6.




Figure 1. Flow chart of study selection

Intra-individual WMH change

WMH volume change in mL

We identified 27 papers^{4, 5, 10-34} (total 7411 participants) that reported raw WMH volume change over time. Overall time between scans was on average 2.7 years (SD=1.65; median=2 years; range 0.25 - 8.1 years). We combined all data from all populations in one meta-analysis (Figure 2). Overall WMH increased by mean 1.74 mL over time (95% CI 1.23, 2.26 mL), with PI of -1.24, 4.73 mL).

Author	Population	Subgroup	Ν	Age	Mean	MRAW	95%-CI	Weight
Burton et al., 2006	Cognitive	AD	23	72.20		1.70	[0.25; 3.15]	2.3%
Burton et al., 2006	Cognitive	DLB	14	74.20		0.52	[-0.07; 1.12]	2.7%
Burton et al., 2006	Cognitive	PDD	13	74.90		1.73	[0.38; 3.08]	2.3%
Moon et al., 2018	Cognitive	Total group	358	75.80	+	1.80	[1.46; 2.13]	2.8%
Ramirez et al., 2016	Cognitive	AD low SVD	56	67.90	-	0.30	[0.01; 0.59]	2.8%
Ramirez et al., 2016	Cognitive	AD high SVD	57	74.30		1.70	[0.38; 3.02]	2.3%
Steffens et al., 2007	Depression	Total group MDD	161	69.23		1.53	[0.98; 2.08]	2.7%
Khalaf et al., 2015	Depression	Total group MDD	47		-	0.12	[0.02; 0.22]	2.8%
Burton et al., 2006	Healthy/CD	Controls	33	74.40		1.68	[0.31; 3.05]	2.3%
Callisaya et al., 2015	Healthy/CD		187	70.50	+	0.99	[0.62; 1.36]	2.8%
Firbank et al., 2007	Healthy/CD	Controls	41	76.00		0.52	[-0.09; 1.12]	2.7%
Garde et al., 2005	Healthy/CD		26	80.70		4.60	[2.60; 6.60]	1.9%
Godin et al., 2009	Healthy/CD		1319	72.40		1.40	[1.25; 1.55]	2.8%
Gopalan et al., 2014	Healthy/CD	Placebo	42	52.00	+	0.38	[0.14; 0.62]	2.8%
Gopalan et al., 2014	Healthy/CD	T3 drug	46	52.00	+	-0.03	[-0.26; 0.20]	2.8%
Kneihsl et al., 2020	Healthy/CD		293	60.70		1.20	[0.82; 1.58]	2.8%
Lee et al., 2017	Healthy/CD		450	65.90		4.06	[3.38; 4.74]	2.7%
Marquine et al., 2010	Healthy/CD		110	70.65	•••	1.21	[0.78; 1.64]	2.8%
Nebes et al., 2002	Healthy/CD	Controls	12	73.50		1.40	[-0.07; 2.88]	2.2%
Ramirez et al., 2016	Healthy/CD	Controls		69.40		0.80	[0.21; 1.39]	2.7%
Raz et al., 2013	Healthy/CD			53.00			[0.11; 0.34]	2.8%
Sachdev et al., 2007	Healthy/CD			70.96			[4.38; 8.58]	1.8%
Switzer et al., 2016	Healthy/CD	Controls		68.40			[-0.06; 0.93]	2.8%
Taylor et al., 2003	Healthy/CD			69.10			[0.85; 1.95]	2.7%
Van Sloten et al., 2015	Healthy/CD	Total		74.60	· · · · · · · · · · · · · · · · · · ·		[5.64; 6.36]	2.8%
Whitman et al., 2001	Healthy/CD			79.00			[0.68; 1.52]	2.8%
De Havenon et al., 2019		Cohort 1		62.70			[0.83; 1.03]	2.8%
Firbank et al., 2007	Other VRF	Placebo	47				[0.93; 2.79]	2.6%
Firbank et al., 2007	Other VRF	Candesartan	45				[0.36; 2.26]	2.6%
Gouw et al., 2008	Other VRF	SVD	20				[2.36; 6.84]	1.8%
Van Elderen et al., 2010		DM		74.70	· · · · · · · · · · · · · · · · · · ·		[1.72; 1.84]	2.8%
Van Elderen et al., 2010		Controls		75.00			[2.19; 2.23]	2.8%
Van Leijsen et al., 2017	Other VRF	Overall change		62.50			[3.92; 5.48]	2.7%
Yoon et al., 2017	Other VRF	Controls		60.90			[0.47; 1.10]	2.8%
Yoon et al., 2017		Antiplatelet drugs		60.50	<mark>≕</mark> _		[0.80; 1.64]	2.8%
Switzer et al., 2016	Stroke	CAA		72.60			[0.26; 5.46]	1.6%
Wardlaw et al., 2017	Stroke			65.30			[0.07; 2.47]	2.4%
Xiong et al., 2014	Stroke	Statin use		76.87			[2.79; 7.23]	1.8%
Xiong et al., 2014	Stroke	Nonstatin use	47	73.59		1.54	[0.24; 2.84]	2.4%
Random effects model					↓		[1.23; 2.26]	100.0%
Prediction interval							[-1.24; 4.73]	
Heterogeneity: $I^2 = 99\%$, τ^2	^c = 2.1053, p :	= 0						
					-5 0 5			

Figure 2. Random-effects meta-analysis of raw mean WMH volume change in mL over median 2 years, range 0.25 - 8.1 years. Squares represent means and bars the 95%CI. Note: AD: Alzheimer's disease; CAA: Cerebral amyloid angiopathy; DLB: Lewy Body Dementia; DM: Diabetes Mellitus; Healthy/CD: Healthy/community-dwelling; MDD: Major depressive disorder; MRAW: Raw means; PDD: Parkinson's disease dementia; SVD: Small vessel disease; VRF: Vascular risk factors

Change in %ICV

Six studies reported WMH and their change over time as %ICV³⁵⁻⁴⁰ (total 1071 participants), with time between MRI mean 3.5 years (SD=1.54. Median=3; range 1.9 – 6.7) were metaanalysed (Figure 3). WMH volume as %ICV shows an increase of 0.25 (95% CI 0.14, 0.36; PI -0.06, 0.56) %ICV.




Figure 3. Random-effects meta-analysis of mean WMH volume change as %ICV over median of 3 years, range 1.9 – 6.7 years. Squares represent means and bars the 95%CI. Note: DM2: Diabetes Mellitus type 2; Healthy/CD: Healthy/community-dwelling; MRAW: Raw means; VRF: Vascular risk factors

WMH change in mL per year

Seven studies⁴¹⁻⁴⁷ (total 2450 participants) reported the unadjusted mean WMH change per

year (Figure 4). Overall, mean WMH change showed an increase of 0.61 (95% CI 0.37,

0.85; PI -0.25, 1.46) ml/year.




Figure 4. Random-effects meta-analysis of mean WMH volume in mL/year. Squares represent means and bars the 95% CI. Note: AD: Alzheimer's disease; CAA: Cerebral amyloid angiopathy; Healthy/CD: healthy/community-dwelling; MCI: Mild cognitive impairment; MRAW: raw means; NC: normal controls; VRF: Vascular risk factors

Subgroup analyses

For explorative purposes, we examined WMH change per population type and, when possible, by age and time lapse between scans.

Population

We performed meta-analyses per population group for all three ways of reporting WMH change (mL, %ICV, mL/year). Where studies reported treatment groups, control or case groups, these subgroups are reported. Not all population groups were available for %ICV and mL/year.

WMH raw volume increased by 1.78 mL (95% CI 0.83, 2.73; PI -2.18, 5.75; eFigure 1) in healthy and community-dwelling population over 2.9 ± 1.3 years (range 1 - 5.3).^{10, 11, 13-16, 19-21,} ^{23-26, 28, 29, 31, 33} WMH %ICV increased by 0.26 %ICV (95% CI 0.09, 0.43; PI -0.20, 0.71; eFigure 2), over 1.9 - 6.7 years^{35-37, 40} and the annual rate by 0.62 mL/year (95% CI 0.02, 1.22; PI -1.03, 2.27; eFigure 3).^{41, 42, 44, 46}

In people with memory complaints²² and dementia^{10, 24} WMH increased by mean 1.17 mL (95% CI 0.40, 1.94; PI -0.87, 3.20; eFigure 4). Among mild cognitive impairment and Alzheimer's dementia groups, WMH increased by 0.27mL/year (95% CI 0.02, 0.51; PI -0.07, 0.60; eFigure 5).^{42, 44}


In people with depression, WMH volume increased by 1.19 mL (95% CI -1.81, 4.18; PI -6.90, 9.27; eFigure 6).^{18, 27} Within the depression populations, a group with incident dementia at follow up²⁷ presented the largest mean WMH volume increase with 4.52mL (95% CI 2.25, 6.79), while the raw mean volume changes for the other depression groups range from 0.08-1.10 mL.


Among populations recruited because of vascular risk factors (VRF), i.e., participants with diabetes,^{12, 35} SVD,^{4, 17} multiple risk factors,^{32, 47} hypertension,^{13, 38} and vascular disease or high risk of vascular disease,³⁰ WMH volume also increased on average, including increases of 2.02mL (95% CI 0.95, 3.09; PI -1.19, 5.23; eFigure 7),^{4, 12, 13, 17, 30, 32} 0.30%ICV (95% CI - 0.14, 0.74; PI -2.22, 2.81; eFigure 8),^{35, 38}, and 0.71 mL/year (95% CI 0.53, 0.89; PI not calculable; eFigure 9).⁴⁷

Data on stroke patients was available for WMH volume in mL, increase of 2.46 mL (95% CI - 0.21, 5.12; PI -4.50, 9.41; eFigure 10),^{5, 28, 34} and mL per year, an increase of 0.72 mL/year (95% CI -1.32, 2.76; PI not calculable; eFigure 11).^{43, 45}

Time between scans

Most studies had a follow up time between scans of around two years. The 27 papers reporting raw volume in mL had a follow-up time of 2.7 ± 1.65 years (median=2, range 0.25 - 8.7). Longer follow up times between scans appeared associated with larger WMH increase in mL (Figure 5). In a similar bubble plot of mean WMH change as %ICV (3.5 ± 1.54 years, median=3; range 1.9 - 6.7), there is no clear relation between longer time between scans and larger WMH change (Figure 6) but there were far fewer studies.








Figure 6. Bubble plot of mean WMH change (%ICV), in individual studies, related to time between scans (years). Points in plot are scaled by sample size and colour of points refer to population group.

Age

Patterns in the bubble plots of WMH change versus mean age at baseline suggest that WMH volume change increases at older ages across WMH in mL (Figure 7), %ICV (eFigure 12) and mL/year (eFigure 13), with a younger mean age at baseline generally corresponding to smaller WMH change over time.




Figure 7. Bubble plot of mean WMH change (mL) related to age at baseline (years). Points in plot are scaled by sample size and colour of points refer to population group.

WMH regression

Thirteen of the 39 papers (eTables 3-5) included in the meta-analysis mentioned WMH volume regression, of which WMH volume regression was discussed by 8/13 papers,^{4, 5, 11, 16, 24, 26, 45, 46} but only 7/8 papers^{5, 10, 16, 22, 23, 25, 28} provided data. One paper⁴⁶ did not mention regression but showed WMH regression in a figure with individual trajectories. WMH regression was found in healthy/community-dwelling participants (in ~34%¹¹ and 17%²⁶) and in stroke participants (4%⁴⁵ and 37%⁵). Areas of WMH shrinkage were found in AD participants with high SVD load, with less WMH regression in cognitively normal controls who had less WMH at baseline than the patients with AD and high SVD load.²⁴ Over 9-years follow-up⁴ (n=276), one participant (0.4%) showed net WMH regression, while 9% showed regression in the first follow-up period (2006-2011) and 2% in the second period (2011-2015). Factors associated with WMH regression were not found.⁴⁸ Observations of WMH

regression from papers not included in meta-analysis (eTable 6) can be found in eResult1, and associations with WMH change in eResult2.

Discussion

Our meta-analyses suggest that although WMH volumes increase on average, WMH volumes also regress, with WMH volume regression occurring explicitly in up to 1/3 of participants. The prediction intervals of the main analyses of WMH change capture the extent of WMH volume regression (-1.24 mL; -0.06 %ICV; -0.25 mL/year) and increase (4.73 mL; 0.56 %ICV; 1.46 mL/year). We show that WMH regression can occur in all typical populations affected by SVD, greater WMH volume change might occur at older age, and WMH regression might occur over a wide range of follow-up times.

As WMH progression is the main focus of most papers and WMH regression is regarded as an accidental finding or even an 'error', the underlying mechanisms of WMH regression are unknown, or whether regression represents improvement in tissue health and translates to a positive effect on clinical outcomes.⁴⁸ However, some evidence suggests that regression is linked to less cognitive decline, recurrent stroke or dependency.⁴⁹ Furthermore, if patients with less WMH progression have less cognitive impairment than those with more WMH progression, then there is reason to think that WMH regression might translate to even better outcomes.

The papers included had several limitations. First, methodologies to measure and report WMH volume change, i.e. mL, %ICV, or mL/year, varied and complicated the comparison of volume change, and means that the findings should be interpreted with caution. Although there are many methods to assess WMH volume, including artificial intelligence approaches, there is little cross-validation or standardisation. Furthermore, methods specifically addressing WMH volume change that account for registration steps are only beginning to emerge.⁵⁰ Second, papers that report WMH volume change as an annualised rate might represent a bias by assuming that change is linear. We did not find a clear relation between longer follow-up times and larger WMH volume change but this may reflect the heterogeneity

of studies, populations and follow-up times. A study with a 9-year follow-up period⁴ shows that WMH volumes can both increase and decrease within the 9 years and that more people had WMH regression in the first five years than in the second part. Thus, studies reporting annualized rates should also report the absolute change over time at the final time point. Our analyses were limited by not being able to examine factors related to regression since too few papers examined these. For the same reason, we were unable to assess the effect of interventions on WMH volume regression.

The strengths of our review include a comprehensive literature search of WMH volume change using different measurements of WMH volume; subgroup exploratory analyses into differences between populations, age and follow-up times; and a good geographical coverage of included studies. The review uses prediction intervals to show least and most change, rather than only confidence intervals which focus on the mean and thus obscure the true limits of change. Hence the review demonstrates the range of inter-individual differences in WMH progression volume that may have been overlooked through the tendency in previous studies to focus solely on WMH progression.

Future studies should examine WMH change including the possibility of WMH regression and investigate WMH change over a long period of time. The median follow-up times in our main analyses were 2 years (mL) and 3 years (%ICV), providing little evidence over longer follow-times². Longer follow-up times and scans at multiple time-points would provide more information on trajectories of volume change and dynamics of WMH. Additionally, examination of possible pathological, imaging and clinical factors related to WMH regression is vital as the exact underlying mechanisms and clinical consequences are unknown. In conclusion, our results indicate that WMH volumes can regress over time in diverse populations, while net WMH volume might progress. However, little is known about underlying mechanisms of WMH volume regression while WMH changes might represent an opportunity to develop new interventions and delay the progression of WMH and its devastating clinical consequences.

Disclosure None

Funding

ACCJ was funded by the Alzheimer's Society (ref 486 (AS-CP-18b-001), University of Edinburgh College of Medicine and Veterinary Medicine and the UK Dementia Research Institute which receives funding from UK DRI Ltd funded by the UK Medical Research Council, Alzheimer's Society and Alzheimer's Research UK. CA is funded by UK Dementia Research Institute as above, the Mexican National Council of Science and Technology (CONACYT) and the Anne Rowling Regenerative Neurology Clinic. TR and MH were funded by the Wellcome Trust through the Translational Neurosciences PhD program. SMM was funded by Age UK. FND acknowledges support from The Stroke Association, Garfield Weston Foundation, NHS Research Scotland and the Agnes Parry Endowment at the University of Edinburgh. JMW acknowledges support from the Fondation Leducq Transatlantic Network of Excellence for the Study of Perivascular Spaces in Small Vessel Disease (16 CVD 05) and the UK Dementia Research Institute as above.

References

1. Wardlaw JM, Smith EE, Biessels GJ, Cordonnier C, Fazekas F, Frayne R, Lindley RI, O'Brien JT, Barkhof F, Benavente OR, et al. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. *Lancet Neurol*. Aug 2013;12:822-38. doi:10.1016/S1474-4422(13)70124-8

2. Brown R, Low A, Markus HS. Rate of, and risk factors for, white matter hyperintensity growth: a systematic review and meta-analysis with implications for clinical trial design. *Journal of Neurology, Neurosurgery & Psychiatry*. 2021;jnnp-2021-326569.

doi:10.1136/jnnp-2021-326569

3. Debette S, Markus HS. The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: systematic review and meta-analysis. *BMJ*. Jul 26 2010;341:c3666. doi:10.1136/bmj.c3666

4. van Leijsen EMC, van Uden IWM, Ghafoorian M, Bergkamp MI, Lohner V, Kooijmans ECM, van der Holst HM, Tuladhar AM, Norris DG, van Dijk EJ, et al. Nonlinear temporal dynamics of cerebral small vessel disease: The RUN DMC study. *Neurology*. Oct 10 2017;89:1569-1577. doi:10.1212/WNL.000000000004490

5. Wardlaw JM, Chappell FM, Valdés Hernández MdC, Makin SDJ, Staals J, Shuler K, Thrippleton MJ, Armitage PA, Muñoz-Maniega S, Heye AK, et al. White matter hyperintensity reduction and outcomes after minor stroke. *Neurology*. 2017;89:1003-1010. doi:10.1212/wnl.000000000004328

6. Kim SY, Park JE, Lee YJ, Seo H-J, Sheen S-S, Hahn S, Jang B-H, Son H-J. Testing a tool for assessing the risk of bias for nonrandomized studies showed moderate reliability and promising validity. *Journal of clinical epidemiology*. 2013;66:408-414.

doi:10.1016/j.jclinepi.2012.09.016

7. Shi J, Luo D, Weng H, Zeng XT, Lin L, Chu H, Tong T. Optimally estimating the sample standard deviation from the five-number summary. *Research synthesis methods*. 2020;11:641-654. doi:10.1002/jrsm.1429

8. Knapp G, Hartung J. Improved tests for a random effects meta-regression with a single covariate. *Statistics in medicine*. 2003;22:2693-2710. doi:10.1002/sim.1482

9. Balduzzi S, Rücker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. *Evidence-based mental health*. 2019;22:153-160.

10. Burton EJ, McKeith IG, Burn DJ, Firbank MJ, O'Brien JT. Progression of White Matter Hyperintensities in Alzheimer Disease, Dementia With Lewy Bodies, and Parkinson Disease Dementia: A Comparison With Normal Aging. *The American Journal of Geriatric Psychiatry*. 2006/10/01/ 2006;14:842-849. doi:10.1097/01.JGP.0000236596.56982.1c

11. Callisaya ML, Beare R, Phan T, Blizzard L, Thrift AG, Chen J, Srikanth VK. Progression of White Matter Hyperintensities of Presumed Vascular Origin Increases the Risk of Falls in Older People. *The Journals of Gerontology: Series A*. 2015;70:360-366. doi:10.1093/gerona/glu148

12. de Havenon A, Majersik JJ, Tirschwell DL, McNally JS, Stoddard G, Rost NS. Blood pressure, glycemic control, and white matter hyperintensity progression in type 2 diabetics. *Neurology*. 2019;92:e1168-e1175. doi:10.1212/wnl.00000000000000093

13. Firbank MJ, Wiseman RM, Burton EJ, Saxby BK, O'Brien JT, Ford GA. Brain atrophy and white matter hyperintensity change in older adults and relationship to blood pressure. *Journal of Neurology*. 2007;254:713-721. doi:10.1007/s00415-006-0238-4

14. Garde E, Lykke Mortensen E, Rostrup E, Paulson OB. Decline in intelligence is associated with progression in white matter hyperintensity volume. *Journal of Neurology, Neurosurgery & Psychiatry*. 2005;76:1289-1291. doi:10.1136/jnnp.2004.055905

15. Godin OI, Tzourio C, Maillard P, Alpérovitch A, Mazoyer B, Dufouil C. Apolipoprotein E genotype is related to progression of white matter lesion load. *Stroke*. 2009;40:3186-3190. doi:10.1161/STROKEAHA.109.555839

16. Gopalan Y, Shuaib IL, Magosso E, Ansari MA, Bakar MRA, Wong JW, Khan NAK, Liong WC, Sundram K, Ng BH, et al. Clinical Investigation of the Protective Effects of Palm Vitamin E Tocotrienols on Brain White Matter. *Stroke*. 2014;45:1422-1428.

doi:10.1161/STROKEAHA.113.004449

Gouw AA, van der Flier WM, van Straaten ECW, Pantoni L, Bastos-Leite AJ, Inzitari
D, Erkinjuntti T, Wahlund LO, Ryberg C, Schmidt R, et al. Reliability and Sensitivity of Visual
Scales versus Volumetry for Evaluating White Matter Hyperintensity Progression.
Cerebrovascular Diseases. 2008;25:247-253. doi:10.1159/000113863

 Khalaf A, Edelman K, Tudorascu D, Andreescu C, Reynolds CF, Aizenstein H. White Matter Hyperintensity Accumulation During Treatment of Late-Life Depression.

Neuropsychopharmacology. 2015/12/01 2015;40:3027-3035. doi:10.1038/npp.2015.158

19. Kneihsl M, Hofer E, Enzinger C, Niederkorn K, Horner S, Pinter D, Fandler-Hofler S, Eppinger S, Haidegger M, Schmidt R, et al. Intracranial Pulsatility in Relation to Severity and Progression of Cerebral White Matter Hyperintensities. *Stroke*. Nov 2020;51:3302-3309. doi:10.1161/STROKEAHA.120.030478

20. Lee W-J, Jung K-H, Ryu YJ, Lee K-J, Kim J-M, Lee S-T, Chu K, Kim M, Lee SK, Roh J-K. Progression of Cerebral White Matter Hyperintensities and the Associated Sonographic Index. *Radiology*. 2017;284:824-833. doi:10.1148/radiol.2017162064

21. Marquine MaJ, Attix DK, Goldstein LB, Samsa GP, Payne ME, Chelune GJ, Steffens DC. Differential patterns of cognitive decline in anterior and posterior white matter hyperintensity progression. *Stroke*. 2010;41:1946-1950.

doi:10.1161/STROKEAHA.110.587717

22. Moon SY, de Souto Barreto P, Rolland Y, Chupin M, Bouyahia A, Fillon L, Mangin JF, Andrieu S, Cesari M, Vellas B. Prospective associations between white matter hyperintensities and lower extremity function. *Neurology*. 2018;90:e1291-e1297. doi:10.1212/wnl.000000000005289

23. Nebes RD, Reynolds III CF, Boada F, Meltzer CC, Fukui MB, Saxton J, Halligan EM, DeKosky ST. Longitudinal increase in the volume of white matter hyperintensities in lateonset depression. *International Journal of Geriatric Psychiatry*. 2002;17:526-530.

doi:10.1002/gps.635

24. Ramirez J, McNeely AA, Berezuk C, Gao F, Black SE. Dynamic progression of white matter hyperintensities in Alzheimer's disease and normal aging: results from the

Sunnybrook Dementia Study. Frontiers in aging neuroscience. 2016;8:62.

doi:10.3389/fnagi.2016.00062

25. Raz L, Jayachandran M, Tosakulwong N, Lesnick TG, Wille SM, Murphy MC, Senjem ML, Gunter JL, Vemuri P, Jack Jr CR, et al. Thrombogenic microvesicles and white matter hyperintensities in postmenopausal women. *Neurology*. 05 Mar 2013;80:911-918.

26. Sachdev P, Wen W, Chen X, Brodaty H. Progression of white matter hyperintensities in elderly individuals over 3 years. *Neurology*. 2007;68:214-222.

doi:10.1212/01.wnl.0000251302.55202.73

Steffens DC, Potter GG, McQuoid DR, MacFall JR, Payne ME, Burke JR, Plassman BL, Welsh-Bohmer KA. Longitudinal Magnetic Resonance Imaging Vascular Changes, Apolipoprotein E Genotype, and Development of Dementia in the Neurocognitive Outcomes of Depression in the Elderly Study. *The American Journal of Geriatric Psychiatry*. 2007/10/01/ 2007;15:839-849. doi:10.1097/JGP.0b013e318048a1a0

28. Switzer AR, McCreary C, Batool S, Stafford RB, Frayne R, Goodyear BG, Smith EE. Longitudinal decrease in blood oxygenation level dependent response in cerebral amyloid angiopathy. *NeuroImage: Clinical*. 2016;11:461-467. doi:10.1016/j.nicl.2016.02.020

29. Taylor WD, MacFall JR, Provenzale JM, Paynel ME, McQuoid DR, Steffens DC, Krishnan KRR. Serial MR imaging of volumes of hyperintense white matter lesions in elderly patients: Correlation with vascular risk factors. *American Journal of Roentgenology*. 01 Aug 2003;181:571-576. doi:10.2214/ajr.181.2.1810571

30. Van Elderen SGC, De Roos A, De Craen AJM, Westendorp RGJ, Blauw GJ, Jukema JW, Bollen ELEM, Middelkoop HAM, Van Buchem MA, Van Der Grond J. Progression of brain atrophy and cognitive decline in diabetes mellitus: A 3-year follow-up. *Neurology*. 14 Sep 2010;75:997-1002. doi:10.1212/WNL.0b013e3181f25f06

31. Van Sloten TT, Sigurdsson S, Van Buchem MA, Phillips CL, Jonsson PV, Ding J, Schram MT, Harris TB, Gudnason V, Launer LJ. Cerebral small vessel disease and association with higher incidence of depressive symptoms in a general elderly population: The AGES-reykjavik study. *American Journal of Psychiatry*. June 2015;172:570-578. doi:10.1176/appi.ajp.2014. 14050578

32. Yoon CW, Choi Y, Jeon S, Lee DH, Yoon B-N, Park H-K, Rha J-H. Is antiplatelet treatment effective at attenuating the progression of white matter hyperintensities? *PLoS ONE*. 2017;12:e0176300. doi:10.1371/journal.pone.0176300

33. Whitman GT, Tang T, Lin A, Baloh RW. A prospective study of cerebral white matter abnormalities in older people with gait dysfunction. *Neurology*. 25 Sep 2001;57:990-994. doi:10.1212/wnl.57.6.990

Xiong Y, Wong A, Cavalieri M, Schmidt R, Chu WWC, Liu X, Wong KS, Mok V.
Prestroke Statins, Progression of White Matter Hyperintensities, and Cognitive Decline in
Stroke Patients with Confluent White Matter Hyperintensities. *Neurotherapeutics*. 2014/07/01
2014;11:606-611. doi:10.1007/s13311-014-0270-5

35. de Bresser J, Tiehuis AM, van den Berg E, Reijmer YD, Jongen C, Kappelle LJ, Mali WP, Viergever MA, Biessels GJ, Group obotUDES. Progression of Cerebral Atrophy and White Matter Hyperintensities in Patients With Type 2 Diabetes. *Diabetes Care*. 2010;33:1309-1314. doi:10.2337/dc09-1923

36. Dickie DA, Karama S, Ritchie SJ, Cox SR, Sakka E, Royle NA, Aribisala BS, Hernández MV, Maniega SM, Pattie A, et al. Progression of White Matter Disease and Cortical Thinning Are Not Related in Older Community-Dwelling Subjects. *Stroke*. 2016;47:410-416. doi:10.1161/STROKEAHA.115.011229

37. Moscufo N, Wolfson L, Meier D, Liguori M, Hildenbrand PG, Wakefield D, Schmidt JA, Pearlson GD, Guttmann CR. Mobility decline in the elderly relates to lesion accrual in the splenium of the corpus callosum. *Age*. 2012;34:405-414. doi:10.1007/s11357-011-9242-4

38. White WB, Wakefield DB, Moscufo N, Guttmann CRG, Kaplan RF, Bohannon RW, Fellows D, Hall CB, Wolfson L. Effects of intensive versus standard ambulatory blood pressure control on cerebrovascular outcomes in older people (INFINITY). *Circulation*. 12 Nov 2019;140:1626-1635. doi:10.1161/CIRCULATIONAHA.119.041603

 Wyss A, Dawson J, Arba F, Wardlaw JM, Dickie DA. Combining Neurovascular and Neurodegenerative Magnetic Resonance Imaging Measures in Stroke. *Stroke*.
2019;50:1136-1139. doi:10.1161/STROKEAHA.118.024181

40. Xia Y, Shen Y, Wang Y, Yang L, Wang Y, Li Y, Liang X, Zhao Q, Wu J, Chu S, et al. White matter hyperintensities associated with progression of cerebral small vessel disease: a 7-year Chinese urban community study. Research Support, Non-U.S. Gov't. *Aging*. 05 10 2020;12:8506-8522. doi:10.18632/aging.103154

41. Akoudad S, Ikram MA, Koudstaal PJ, Hofman A, Niessen WJ, Greenberg SM, Van Der Lugt A, Vernooij MW. Cerebral microbleeds are associated with the progression of ischemic vascular lesions. *Cerebrovascular Diseases*. 2014;37:382-388.

doi:10.1159/000362590

42. Carmichael O, Schwarz C, Drucker D, Fletcher E, Harvey D, Beckett L, Jack CR, Jr, Weiner M, DeCarli C, Initiative AsDN. Longitudinal Changes in White Matter Disease and Cognition in the First Year of the Alzheimer Disease Neuroimaging Initiative. *Archives of Neurology*. 2010;67:1370-1378. doi:10.1001/archneurol.2010.284

43. Chen Y, Gurol M, Rosand J, Viswanathan A, Rakich S, Groover T, Greenberg S, Smith E. Progression of white matter lesions and hemorrhages in cerebral amyloid angiopathy. *Neurology*. 2006;67:83-87. doi:10.1212/01.wnl.0000223613.57229.24.

44. Maillard P, Carmichael O, Harvey D, Fletcher E, Reed B, Mungas D, DeCarli C.FLAIR and Diffusion MRI Signals Are Independent Predictors of White Matter

Hyperintensities. American Journal of Neuroradiology. 2013;34:54-61.

doi:10.3174/ajnr.A3146

Sam K, Crawley AP, Conklin J, Poublanc J, Sobczyk O, Mandell DM,
Venkatraghavan L, Duffin J, Fisher JA, Black SE, et al. Development of White Matter
Hyperintensity Is Preceded by Reduced Cerebrovascular Reactivity. *Annals of Neurology*.
2016;80:277-285. doi:10.1002/ana.24712

46. Scharf EL, Graff-Radford J, Przybelski SA, Lesnick TG, Mielke MM, Knopman DS, Preboske GM, Schwarz CG, Senjem ML, Gunter JL, et al. Cardiometabolic Health and

Longitudinal Progression of White Matter Hyperintensity. *Stroke*. 2019;50:3037-3044. doi:10.1161/STROKEAHA.119.025822

47. Van Dalen JW, Moll Van Charante EP, Caan MWA, Scheltens P, Majoie CBLM, Nederveen AJ, Van Gool WA, Richard E. Effect of Long-Term Vascular Care on Progression of Cerebrovascular Lesions. *Stroke*. 01 Jul 2017;48:1842-1848.

doi:10.1161/STROKEAHA.117.017207

48. Kim SJ, Lee DK, Jang YK, Jang H, Kim SE, Cho SH, Kim JP, Jung YH, Kim EJ, Na DL, et al. The Effects of Longitudinal White Matter Hyperintensity Change on Cognitive Decline and Cortical Thinning over Three Years. *Journal of Clinical Medicine*. Aug 17 2020;9:17. doi:10.3390/jcm9082663

49. Al-Janabi OM, Bauer CE, Goldstein LB, Murphy RR, Bahrani AA, Smith CD, Wilcock DM, Gold BT, Jicha GA. White Matter Hyperintensity Regression: Comparison of Brain Atrophy and Cognitive Profiles with Progression and Stable Groups. *Brain Sciences*. 2019;9:170.

50. Bahrani AA, Smith CD, Barber JM, Al-Janabi OM, Powell DK, Andersen AH, Ramey BD, Abner EL, Goldstein LB, Winder Z, et al. Development of a protocol to assess withinsubject, regional white matter hyperintensity changes in aging and dementia. *Journal of Neuroscience Methods*. 2021;360 doi:10.1016/j.jneumeth.2021.109270